FINAL CALL: The Anthem Biosciences IPO closes in just a few hours at 5:00 PM today, July 16th.
If you’re on the fence, here are 5 compelling reasons to consider hitting that ‘Apply’ button right now!
Reason 1: Anthem’s Overwhelming Subscription (20x)
The market has shown significant interest in this IPO, with strong demand coming from institutional and high-net-worth investors. This indicates a healthy appetite for the company’s shares.
As of 2:15 PM, July 16th (Data source: NSE India), the subscription status is as follows:
| Investor Category | Subscription Status |
|---|---|
| Qualified Institutional (QIB) | 39.27x |
| Non-Institutional (NII) | 34.71x |
| Retail Individual (RII) | 4.50x |
| Employee Quota | 5.03x |
| Total Subscription | 20.85x |
Why this matters?
The key number here is the 39.27x demand from QIBs (the “smart money”). This level of institutional interest signals deep confidence in Anthem’s long-term value. Furthermore, the healthy 5x subscription from employees shows that the people inside the company believe in its future. This strong overall demand is a major positive signal for a successful listing.
Reason 2: Anthem IPO GMP Signals Strong Listing
While the Grey Market Premium is an unofficial indicator, its data is actively tracked and aggregated by various IPO-focused websites and financial market observers. It serves as a popular signal for expected listing day performance.
As of 2:15 PM, July 16th, here’s the final GMP signal:
- Today’s Grey Market Premium (GMP): ₹160
- IPO Upper Price Band: ₹570
- Implied Listing Price: ~₹730 (₹570 + ₹160)
- Potential Listing Gain: ₹4160 (~28%)
(Source: GMP data is aggregated from multiple IPO tracking portals and market observers.)
What this means for you?
In simple terms, the market is anticipating that the shares could list at a premium of over 28% above the issue price. For investors applying for listing day gains, this is a very encouraging sign. A stable and high GMP like this often points to a robust market debut.
Reason 3: Strong Consensus from Market Experts
It’s one thing to see market demand, but it’s another when seasoned financial analysts give their stamp of approval. The expert community has a strong positive consensus on the Anthem Biosciences IPO.
Here’s a snapshot of ratings from top brokerage firms:
- Anand Rathi: Recommends “Subscribe – for Long Term ✅,” citing the company’s diverse product portfolio and strong client relationships.
- Motilal Oswal: Has a “Subscribe ✅“ rating, highlighting the company’s robust financial track record and high growth potential in the CRAMS sector.
- SMC Global: Gives a “Subscribe ✅“ recommendation, pointing to reasonable valuations compared to its listed peers.
What this means for you?
When multiple independent research firms analyze a company’s finances, risks, and future prospects and still arrive at the same positive conclusion, it provides a strong layer of validation. It confirms that the company’s fundamentals are solid, making it a more confident choice for your investment.
Reason 4: Investing in a High-Growth Industry Leader
Beyond the market excitement, you are investing in a fundamentally strong business. A quick look at Anthem’s financial journey shows a clear picture of growth and profitability.
A Snapshot of Anthem’s Financial Performance
(The data below is from the company’s RHP/DRHP filings)
Revenue Growth (in ₹ Crores)
A consistent upward trend shows the company is successfully expanding its business year after year.
FY2023 | ████████ (₹650 Cr)
FY2024 | ██████████ (₹780 Cr)
FY2025 | █████████████ (₹950 Cr)
Profit After Tax Growth (in ₹ Crores)
More importantly, profits are growing alongside revenue, indicating strong operational efficiency.
FY2023 | ████████ (₹80 Cr)
FY2024 | ██████████ (₹105 Cr)
FY2025 | ████████████ (₹140 Cr)
These strong fundamentals are built on a solid business model:
- Proven Financials: The charts above speak for themselves. The company has a proven track record of growing both its revenue and profits at an impressive rate.
- The Right Place, The Right Time: Anthem is a key player in the high-growth CRAMS sector. It’s the ‘one-stop-shop’ for global pharma giants who need to outsource R&D and manufacturing, a trend that is only accelerating.
- Trusted by Global Giants: Earning and retaining clients from the global biopharma industry requires rigorous quality standards. Anthem’s strong client base is a testament to its operational excellence.
What this means for you?
This isn’t just a short-term trade. You are buying a stake in a company with a proven history of execution. Its crucial role in the growing global pharma supply chain provides a strong foundation for future value creation.
Reason 5: The Window of Opportunity is Closing Fast
We’ve seen the strong market demand, the healthy GMP, the unanimous expert ratings, and the solid financial growth. All signs point to a high-quality market event.
Good companies like this don’t offer their shares at a fixed IPO price very often. After 5:00 PM today, this specific opportunity to invest at the ground-floor level will be gone.
What this means for you: This is your final chance to be part of Anthem Biosciences’ journey from day one as a publicly-listed company. The decision you make in the next couple of hours will determine whether you get shares at the issue price or have to buy them from the open market later, potentially at a much higher price.
How to Apply in the Next 5 Minutes (Before 5 PM)
Ready to proceed? The process is simple and fast.
- Open Your Brokerage App: Log in to Zerodha, Upstox, Groww, Angel One, or whichever app you use.
- Find the IPO Section: It’s usually on the main dashboard. Click on it and select “Anthem Biosciences”.
- Place Your Bid: Enter your desired number of lots. Crucially, select the “Cut-Off Price” option to ensure your application is considered at the final issue price.
- Confirm and Pay: Enter your UPI ID and submit the application.
- Approve the Mandate: Immediately open your UPI app (GPay, PhonePe, etc.) and approve the payment mandate. Your application is not complete until you do this!
Disclaimer:The information provided in this article is for educational and informational purposes only and does not constitute financial advice. All equity investments are subject to market risks. Please consult with your registered financial advisor before making any investment decisions.
Beyond his passion for technology, Kushal is also an experienced trader and investor with over five years of experience in the financial markets, specializing in swing and intraday trading of stocks, futures, and options.
- 4 Best IPOs to Watch This Week (July 23-29): GNG, Brigade & More! - July 23, 2025
- Anthem Biosciences IPO: 5 Reasons to Apply Before 5 PM Today! - July 16, 2025
- Travel Food IPO GMP, Subscription, Allotment: What to do on Listing? - July 9, 2025